Advanced search
Publication Cover
Cogent Medicine Volume 4, 2017 - Issue 1
Journal homepage
437
Views
0
CrossRef citations to date
0
Altmetric
Research Article

A multi-parameter approach for predicting prostate cancer

Antonio SerafinDivision of Radiobiology, Faculty of Medicine and Health Sciences, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Tygerberg, South AfricaCorrespondence[email protected]
View further author information
,
Angela ChinhengoDivision of Radiobiology, Faculty of Medicine and Health Sciences, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Tygerberg, South Africa
,
Pedro FernandezFaculty of Medicine and Health Sciences, Department of Urology, University of Stellenbosch, Tygerberg, South AfricaORCID Iconhttps://orcid.org/0000-0002-8728-9032
ORCID Icon &
John AkuduguDivision of Radiobiology, Faculty of Medicine and Health Sciences, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Tygerberg, South Africa
|
Udo SchumacherUniversity Medical Center Hamburg-Eppendorf, Germany
(Reviewing Editor)
Article: 1329257 | Received 31 Jan 2017, Accepted 09 May 2017, Published online: 18 May 2017

References

  • Akudugu, J., Serafin, A., & Böhm, L. (2015). Further evaluation of uPA and PAI-1 as biomarkers for prostatic diseases. Journal of Cancer Research and Clinical Oncology, 141, 627–631. doi:10.1007/s00432-014-1848-3
  • Böhm, L., Serafin, A., Akudugu, J., Fernandez, P., van der Merwe, A., & Aziz, N. A. (2013). uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer. Journal of Cancer Research and Clinical Oncology, 139, 1221–1228. doi:10.1007/s00432-013-1428-y
  • Duffy, M. J., McGowan, P. M., Harbeck, N., Thomssen, C., & Schmitt, M. (2014). uPA and PAI-1 as biomarkers in breast cancer: Validated for clinical use in level-of-evidence-1 studies. Breast Cancer Research, 16, 428. doi:10.1186/s13058-014-0428-4
  • Florkowski, C. M. (2008). Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: Communicating the performance of diagnostic tests. The Clinical Biochemist Reviews, 29, S83–S87.
  • Fournier Jr., G. R., & Narayan, P. (1993). Re-evaluation of the need for pelvic lymphadenectomy in low grade prostate cancer. British Journal of Cancer, 72, 484–488.
  • Gondek, T., Szajewski, M., Szefel, J., Aleksandrowicz-Wrona, E., Skrzypczak-Jankun, E., Jankun, J., & Lysiak-Szydlowska, W. (2014). Evaluation of 12-Lipoxygenase (12-LOX) and Plasminogen Activator Inhibitor 1 (PAI-1) as prognostic markers in prostate cancer. Biomedical Research International, 2014, 102478. doi:10.1155/2014/102478
  • Gonzalgo, M. L., Bastian, P. J., Mangold, L. A., Trock, B. J., Epstein, J. I., Walsh, P. C., & Partin, A. W. (2006). Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. Urology, 67, 115–119.10.1016/j.urology.2005.07.037
  • Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., … Thomssen, C. (2013). Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. European Journal of Cancer, 49, 1825–1835. doi:10.1016/j.ejca.2013.01.007
  • Helin, H., Lundin, M., Lundin, J., Martikainen, P., Tammela, T., Helin, H., … Isola, J. (2005). Web-based virtual microscopy in teaching and standardizing Gleason grading. Human Pathology, 36, 381–386.10.1016/j.humpath.2005.01.020
  • Jänicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C., Prechtl, A., & Graeff, H. (1994). Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Research, 54, 2527–2530.
  • Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014). Ovarian cancer. The Lancet, 384, 1376–1388. doi:10.1016/S0140-6736(13)62146-7
  • Matchariyakul, C., Kochakarn, W., Chaimuangraj, S., Leenanupunth, C., & Lertsithichai, P. (2004). A risk index for prostate cancer. International Journal of Urology, 11, 310–315.10.1111/iju.2004.11.issue-5
  • Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012). Beyond PSA: The next generation of prostate cancer biomarkers. Science Translational Medicine, 4, 127rv3. doi:10.1126/scitranslmed.3003180
  • Schmitt, M., Harbeck, N., Brünner, N., Jänicke, F., Meisner, C., Mühlenweg, B. … Thomssen, C. (2011). Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Review of Molecular Diagnostics, 11, 617–634. doi:10.1586/erm.11.47
  • Serafin, A., Böhm, L., Fernandez, P., Achel, D., & Akudugu, J. (2016). The potential of PAI-1 expression in needle biopsies as a predictive marker for prostate cancer. Cogent Medicine, 3, 1183275.
  • Shariat, S. F., & Roehrborn, C. G. (2008). Using biopsy to detect prostate cancer. Reviews in Urology, 10, 262–280.
  • Tabesh, A., Teverovskiy, M., Pang, H.-Y., Kumar, V. P., Verbel, D., Kotsianti, A., & Saidi, O. (2007). Multifeature prostate cancer diagnosis and gleason grading of histological images. IEEE Transactions on Medical Imaging, 26, 1366–1378.10.1109/TMI.2007.898536
  • Van Neste, L., Hendriks, R. J., Dijkstra, S., Trooskens, G., Cornel, E. B., Jannink, S. A., … Schalken, J. A. (2016). Detection of high-grade prostate cancer using a urinary molecular biomarker–based risk score. European Urology, 70, 740–748. doi:10.1016/j.eururo.2016.04.012

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.